Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Ryo Koyama-Nasu"'
Autor:
Murshed H Sarkar, Ryoji Yagi, Yukihiro Endo, Ryo Koyama-Nasu, Yangsong Wang, Ichita Hasegawa, Toshihiro Ito, Ilkka S Junttila, Jinfang Zhu, Motoko Y Kimura, Toshinori Nakayama
Publikováno v:
PLoS ONE, Vol 16, Iss 11, p e0260204 (2021)
While IFNγ is a well-known cytokine that actively promotes the type I immune response, it is also known to suppress the type II response by inhibiting the differentiation and proliferation of Th2 cells. However, the mechanism by which IFNγ suppress
Externí odkaz:
https://doaj.org/article/62f4a8a367f34005a027aa1979cbb21d
Autor:
Akane S. Suzuki, Ryoji Yagi, Motoko Y. Kimura, Chiaki Iwamura, Kenta Shinoda, Atsushi Onodera, Kiyoshi Hirahara, Damon J. Tumes, Ryo Koyama-Nasu, Siiri E. Iismaa, Robert M. Graham, Shinichiro Motohashi, Toshinori Nakayama
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Memory helper T (Th) cells are crucial for secondary immune responses against infectious microorganisms but also drive the pathogenesis of chronic inflammatory diseases. Therefore, it is of fundamental importance to understand how memory T cells are
Externí odkaz:
https://doaj.org/article/e5a450efae4e4f739d1ac74a3a95f8bf
Autor:
Hiroki Takai, Koji Masuda, Tomohiro Sato, Yuriko Sakaguchi, Takeo Suzuki, Tsutomu Suzuki, Ryo Koyama-Nasu, Yukiko Nasu-Nishimura, Yuki Katou, Haruo Ogawa, Yasuyuki Morishita, Hiroko Kozuka-Hata, Masaaki Oyama, Tomoki Todo, Yasushi Ino, Akitake Mukasa, Nobuhito Saito, Chikashi Toyoshima, Katsuhiko Shirahige, Tetsu Akiyama
Publikováno v:
Cell Reports, Vol 9, Iss 1, Pp 48-60 (2014)
Summary: The development of cancer is driven not only by genetic mutations but also by epigenetic alterations. Here, we show that TET1-mediated production of 5-hydroxymethylcytosine (5hmC) is required for the tumorigenicity of glioblastoma cells. Fur
Externí odkaz:
https://doaj.org/article/6e167373836c4249903547f389fae70e
Publikováno v:
International Journal of Molecular Sciences, Vol 18, Iss 7, p 1495 (2017)
Lineage specification is primarily regulated at the transcriptional level and lineage-specific transcription factors determine cell fates. MicroRNAs (miRNAs) are 18–24 nucleotide-long non-coding RNAs that post-transcriptionally decrease the transla
Externí odkaz:
https://doaj.org/article/06464559013b4846b1b9c115d2d05fd8
Autor:
Ryo Koyama-Nasu, Rina Takahashi, Satoshi Yanagida, Yukiko Nasu-Nishimura, Masaaki Oyama, Hiroko Kozuka-Hata, Ryo Haruta, Emi Manabe, Akemi Hoshino-Okubo, Hiroko Omi, Nozomu Yanaihara, Aikou Okamoto, Tadao Tanaka, Tetsu Akiyama
Publikováno v:
PLoS ONE, Vol 8, Iss 1, p e53710 (2013)
The pentaspan membrane glycoprotein CD133 (also known as prominin-1) has been widely used as a marker for both cancer and normal stem cells. However, the function of CD133 has not been elucidated. Here we describe a cancer stem cell line established
Externí odkaz:
https://doaj.org/article/09ab345a1682412e8371b1e5401c2987
Autor:
Hiroko Kozuka-Hata, Yukiko Nasu-Nishimura, Ryo Koyama-Nasu, Hiroko Ao-Kondo, Kouhei Tsumoto, Tetsu Akiyama, Masaaki Oyama
Publikováno v:
PLoS ONE, Vol 7, Iss 8, p e43398 (2012)
BACKGROUND: Glioblastoma is one of the most aggressive tumors with poor prognosis. Although various studies have been performed so far, there are not effective treatments for patients with glioblastoma. METHODOLOGY/PRINCIPAL FINDINGS: In order to sys
Externí odkaz:
https://doaj.org/article/c16e55cf7cc94a148a99791c7c0d421d
Autor:
Ryo Koyama-Nasu, Motoko Y. Kimura, Masahiro Kiuchi, Ami Aoki, Yangsong Wang, Yukiyoshi Mita, Ichita Hasegawa, Yukihiro Endo, Atsushi Onodera, Kiyoshi Hirahara, Shinichiro Motohashi, Toshinori Nakayama
Publikováno v:
Cancer Immunology Research.
Tumor-specific CD8+ T cells play a pivotal role in anti-tumor immunity and are a key target of immunotherapeutic approaches. Intratumoral CD8+ T cells are heterogeneous; Tcf1+ stem-like CD8+ T cells give rise to their cytotoxic progeny – Tim-3+ ter
Autor:
Asuka Shibamiya, Naoya Mimura, Yurie Miyamoto-Nagai, Shuhei Koide, Motohiko Oshima, Ola Rizq, Kazumasa Aoyama, Yaeko Nakajima-Takagi, Kensuke Kayamori, Yusuke Isshiki, Nagisa Oshima-Hasegawa, Tomoya Muto, Shokichi Tsukamoto, Yusuke Takeda, Ryo Koyama-Nasu, Tetsuhiro Chiba, Hiroaki Honda, Koutaro Yokote, Atsushi Iwama, Emiko Sakaida
Publikováno v:
Blood. 140:4240-4241
Autor:
Ryo Koyama-Nasu, Yangsong Wang, Ichita Hasegawa, Yukihiro Endo, Toshinori Nakayama, Motoko Y Kimura
Publikováno v:
International immunology. 34(11)
Cancer immunotherapy utilizes our immune system to attack cancer cells and is an extremely promising strategy for cancer treatment. Although immune-checkpoint blockade, such as anti-PD-1 (programmed cell death 1) antibody, has demonstrated significan
Autor:
Fumie Ihara, Takahide Toyoda, Toshinori Nakayama, Yasuo Iwadate, Masayoshi Kobayashi, Takahiro Aoki, Ryo Koyama-Nasu, Seiichiro Hirono, Ayaka Hara, Tomoo Matsutani, Mariko Takami, Shinichiro Motohashi
Publikováno v:
Cancer Immunology, Immunotherapy
Glioblastoma is the most common and aggressive type of brain tumor with high recurrence and fatality rates. Although various therapeutic strategies have been explored, there is currently no effective treatment for glioblastoma. Recently, the number o